Klotho Neurosciences Highlights Pipeline Progress Toward $8B Neurodegenerative Market; Accelerates KLTO-202 Preclinical and IND-Enabling Studies

Benzinga·08/18/2025 12:37:19

Listen to the news

Key partnerships, regulatory progress, manufacturing advancements, along with significant capital infusion accelerate the development of Klotho-based therapeutics

NEW YORK, Aug. 18, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. (NASDAQ:KLTO) ("Klotho" or "the Company"), a biotechnology company advancing Klotho-based therapeutics for neurodegenerative diseases, provides a strategic update to shareholders highlighting the Company's key milestones and pipeline progress. These achievements strengthen Klotho's position as it advances toward the large and growing market for Amyotrophic Lateral Sclerosis (ALS), Alzheimer's disease, and Parkinson's disease therapies, which is estimated at over $8 billion annually by Grand View Research and others.

Building on its 2025 progress, the Company is positioned to pursue the following key objectives:

Accelerate preclinical and IND-enabling studies for KLTO-202.
Evaluate complementary technologies and acquisitions to enhance pipeline breadth in brain health, organ function, and longevity.
Continue expanding internal capabilities to strengthen R&D, manufacturing, and clinical readiness.

FAQ

Fee Schedule Open Account Deposit & Withdrawal Trading

Terms & Conditions

Client Agreement Privacy Policy Data Disclaimer Security Tips

About Webull

About us Webull Promotions Contact information Announcements

Contact Number : +852 3852 8500Service Email : service@webull.hkBusiness Cooperation : marketinghk@webull.hk

Risk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.

Language

English